Animal Model

JOINN has established a complete anti-metabolic disease efficacy screening model through years of accumulation, which can evaluate the efficacy of anti-diabetic drugs (insulin, GLP-1 targeting drugs), anti-hyperlipidaemia drugs (PCSK9 targeting drugs) and anti-hyperuricemia drugs.Established efficacy evaluation models are as follows:

Antidiabetic

 db/ DB mice, KKAy mice, ZDF rats and other type II diabetes models

 STZ induced diabetic models in mice and rats

 Evaluation model of gastric emptying and intestinal peristalsis in rats and mice

 dog sugar clamp model

 rat sugar clamp model

 rat model of promoting insulin secretion

 model of promoting insulin secretion in cynomolgus monkey

 DIO Model of obesity in mice and rats

 Determination of insulin activity in mice and rabbits

Antihyperlipidemia drugs

 hPCSK9-AAV8 transfected a hyperlipidemia mouse model

 Rabbit hyperlipidemia model induced by high fat feed

 High fat feed induced hyperlipidemia model in rats

 Hyperlipidemia model of ApoE-/- mice was induced by feeding with high fat diet

 Syrian golden hamster model

 In vitro activity model of PCSK9 inhibitors in HepG2 cells

Anti-hyperuric acid drugs

 hypoxanthine induced hyperuricemia in mice and rats

 sodium urate crystal induced rat balloon inflammation model

 Sodium urate crystal induced rat arthritis model